HRP20100595T1 - Derivati 2-amino-kinazolina koji se koriste kao inhibitori beta-sekretaze (bace) - Google Patents
Derivati 2-amino-kinazolina koji se koriste kao inhibitori beta-sekretaze (bace) Download PDFInfo
- Publication number
- HRP20100595T1 HRP20100595T1 HR20100595T HRP20100595T HRP20100595T1 HR P20100595 T1 HRP20100595 T1 HR P20100595T1 HR 20100595 T HR20100595 T HR 20100595T HR P20100595 T HRP20100595 T HR P20100595T HR P20100595 T1 HRP20100595 T1 HR P20100595T1
- Authority
- HR
- Croatia
- Prior art keywords
- propyl
- 4alkyl
- ethyl
- cyclohexyl
- group
- Prior art date
Links
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title claims abstract 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title claims abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150058765 BACE1 gene Proteins 0.000 title 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- -1 hydroxy, methyl Chemical group 0.000 claims 264
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 76
- 229910052739 hydrogen Inorganic materials 0.000 claims 43
- 239000001257 hydrogen Substances 0.000 claims 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 36
- 125000001424 substituent group Chemical group 0.000 claims 36
- 125000003118 aryl group Chemical group 0.000 claims 34
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 29
- 125000005843 halogen group Chemical group 0.000 claims 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 18
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 16
- 125000004452 carbocyclyl group Chemical group 0.000 claims 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 14
- 125000004043 oxo group Chemical group O=* 0.000 claims 14
- 150000002367 halogens Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims 7
- 239000004305 biphenyl Chemical group 0.000 claims 7
- 235000010290 biphenyl Nutrition 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 3
- 201000010374 Down Syndrome Diseases 0.000 claims 3
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- GQRRWNLARRRPRY-UHFFFAOYSA-N 1,4-dihydroquinazolin-2-amine Chemical class C1=CC=C2CNC(N)=NC2=C1 GQRRWNLARRRPRY-UHFFFAOYSA-N 0.000 abstract 1
- 102100021257 Beta-secretase 1 Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 abstract 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59981104P | 2004-08-06 | 2004-08-06 | |
PCT/US2005/028191 WO2006017836A2 (en) | 2004-08-06 | 2005-08-08 | 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100595T1 true HRP20100595T1 (hr) | 2010-12-31 |
Family
ID=35564387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100595T HRP20100595T1 (hr) | 2004-08-06 | 2010-11-05 | Derivati 2-amino-kinazolina koji se koriste kao inhibitori beta-sekretaze (bace) |
Country Status (15)
Country | Link |
---|---|
US (1) | US8436006B2 (sl) |
EP (1) | EP1776349B1 (sl) |
JP (1) | JP4884387B2 (sl) |
CN (1) | CN101035771A (sl) |
AT (1) | ATE483692T1 (sl) |
CY (1) | CY1111086T1 (sl) |
DE (1) | DE602005024004D1 (sl) |
DK (1) | DK1776349T3 (sl) |
ES (1) | ES2351667T3 (sl) |
HR (1) | HRP20100595T1 (sl) |
PL (1) | PL1776349T3 (sl) |
PT (1) | PT1776349E (sl) |
RS (1) | RS51630B (sl) |
SI (1) | SI1776349T1 (sl) |
WO (1) | WO2006017836A2 (sl) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8426429B2 (en) * | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8383637B2 (en) * | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
TWI332005B (en) | 2005-06-14 | 2010-10-21 | Schering Corp | Aspartyl protease inhibitors |
EP1966198B1 (en) * | 2005-10-25 | 2011-03-16 | Janssen Pharmaceutica NV | 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace) |
US7776882B2 (en) * | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
WO2007092839A2 (en) * | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | Macrocycle derivatives useful as inhibitors of beta-secretase (bace) |
US7868022B2 (en) | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
US8168641B2 (en) | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
WO2008073365A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
CA2687750C (en) * | 2007-07-06 | 2016-10-18 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
EP2205596A1 (en) * | 2007-09-24 | 2010-07-14 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
WO2009062200A1 (en) * | 2007-11-09 | 2009-05-14 | University Of Tennessee Research Foundation | Anti-inflammatory quinic acid derivatives for oral administration |
CN101925578B (zh) * | 2008-01-28 | 2012-11-28 | 詹森药业有限公司 | 可用作β-分泌酶(BACE)抑制剂的6-取代-硫代-2-氨基-喹啉衍生物 |
JP2011510993A (ja) * | 2008-01-29 | 2011-04-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | β−セクレターゼ(BACE)阻害剤として有用な2−アミノ−キノリン誘導体 |
AU2009239535A1 (en) | 2008-04-22 | 2009-10-29 | Schering Corporation | Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
JP2012505241A (ja) * | 2008-10-10 | 2012-03-01 | パーデュー・リサーチ・ファウンデーション | アルツハイマー病の治療用組成物 |
JP2012509352A (ja) * | 2008-11-20 | 2012-04-19 | パーデュー・リサーチ・ファウンデーション | Bace1のキナゾリン阻害剤および使用方法 |
US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
CN103596939A (zh) * | 2011-04-13 | 2014-02-19 | 默沙东公司 | 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用 |
US9499502B2 (en) | 2011-04-13 | 2016-11-22 | Merck Sharp & Dohme Corp. | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use |
WO2013148130A1 (en) * | 2012-03-29 | 2013-10-03 | Oklahoma Medical Research Foundation | Inhibition of memapsin 1 cleavage in the treatment of diabetes |
CA2902080A1 (en) | 2013-02-25 | 2014-08-28 | Merck Patent Gmbh | 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors |
EP3737382A1 (en) * | 2018-01-10 | 2020-11-18 | Cura Therapeutics, LLC | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138595A (en) | 1962-12-03 | 1964-06-23 | American Home Prod | Nu-(cycloalkyl)-pteridinecarboxamides |
US3932407A (en) | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
US3983120A (en) | 1974-11-06 | 1976-09-28 | Bristol-Myers Company | Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones |
US3988340A (en) | 1975-01-23 | 1976-10-26 | Bristol-Myers Company | 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones |
US4001237A (en) * | 1976-02-18 | 1977-01-04 | Bristol-Myers Company | Oxazole, isoxazole, thiazole and isothiazole amides |
NL7807507A (nl) | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
CA1131631A (en) | 1979-06-20 | 1982-09-14 | Madhukar S. Chodnekar | Quinazoline derivatives and pharmaceutical preparations |
ZA803535B (en) | 1979-06-20 | 1981-06-24 | Hoffmann La Roche | Novel quinazoline derivatives and pharmaceutical preparations |
NZ197420A (en) * | 1980-07-01 | 1984-04-27 | Ici Australia Ltd | -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives |
JPS57123184A (en) | 1980-12-16 | 1982-07-31 | Hoffmann La Roche | Novel manufacture of imidazoquinazolinone derivative |
US4455311A (en) | 1981-08-28 | 1984-06-19 | Hoffmann-La Roche Inc. | Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system |
ZA826088B (en) | 1981-08-28 | 1983-04-27 | Hoffmann La Roche | Novel imidazoquinazoline derivatives |
JPS6028979A (ja) | 1983-07-14 | 1985-02-14 | Dai Ichi Seiyaku Co Ltd | イミダゾキナゾリン類化合物 |
US5684153A (en) | 1984-08-16 | 1997-11-04 | Beecham Group Plc | Process for the preparation of purine derivatives |
GB8514207D0 (en) | 1985-06-05 | 1985-07-10 | Pfizer Ltd | Cardiac stimulants |
US4783467A (en) | 1985-06-05 | 1988-11-08 | Pfizer Inc. | Tetrahydroimidazoquinazolinone inotropic agents |
US4761416A (en) | 1986-07-25 | 1988-08-02 | Syntex (U.S.A.) Inc. | N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds |
US4739056A (en) | 1986-11-26 | 1988-04-19 | Syntex (U.S.A.) Inc. | N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds |
JPH0730046B2 (ja) | 1987-02-10 | 1995-04-05 | 第一製薬株式会社 | キナゾリン酢酸誘導体 |
JP2544939B2 (ja) | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
NZ234186A (en) * | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
EP0647268B1 (en) | 1990-06-15 | 2004-03-03 | Scios Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
JPH04112255A (ja) | 1990-09-03 | 1992-04-14 | Casio Comput Co Ltd | ターミナル識別データ設定方式 |
DE69233774D1 (de) | 1991-01-21 | 2009-12-10 | Elan Pharm Inc | Prüfung und Modell für Alzheimers-Krankheit |
US5672805A (en) | 1991-07-18 | 1997-09-30 | The Regents Of The University Of California | Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein |
AU2765992A (en) | 1991-10-03 | 1993-05-03 | Indiana University Foundation | Method for screening for alzheimer's disease |
WO1993014200A1 (en) | 1992-01-07 | 1993-07-22 | Tsi Corporation | Transgenic animal models for alzheimer's disease |
SE511886C2 (sv) | 1992-01-31 | 1999-12-13 | Svedala Arbra Ab | Sätt att styra en gyratorisk kross |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5958883A (en) | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
ATE198622T1 (de) | 1993-10-27 | 2001-01-15 | Elan Pharm Inc | Transgene tiere, die app allele mit der schwedischen mutation beherbergen |
JPH07132033A (ja) | 1993-11-12 | 1995-05-23 | Hoechst Japan Ltd | アルツハイマー病モデルトランスジェニック動物 |
US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
CA2198451A1 (en) | 1994-09-01 | 1996-03-07 | Gurparkash Singh | Transgenic animal expressing a familial form of human amyloid precursor protein |
JPH08151377A (ja) | 1994-11-25 | 1996-06-11 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
US6071903A (en) * | 1998-01-27 | 2000-06-06 | American Cyanamid Company | 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids |
NZ513006A (en) | 1999-01-22 | 2003-10-31 | Kirin Brewery | Quinoline derivatives and quinazoline derivatives |
BR0015718A (pt) | 1999-11-22 | 2002-07-23 | Warner Lambert Co | Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina |
DE60020595T2 (de) | 1999-11-23 | 2006-03-16 | Smithkline Beecham Corp. | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
AU2003223970B2 (en) | 2002-03-22 | 2008-03-06 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
DE10301105B4 (de) | 2003-01-09 | 2005-11-24 | Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh | Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
US7294642B2 (en) * | 2002-09-06 | 2007-11-13 | Elan Pharmaceuticals, Inc. | 1,3-Diamino-2-hydroxypropane pro-drug derivatives |
EP1407774A1 (en) | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
EP1606280A4 (en) | 2003-03-18 | 2008-12-24 | Merck & Co Inc | CYCLOPENTYL HETEROCYLIC TETRAHYDROPYRANYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
GB0325830D0 (en) | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
WO2006017844A1 (en) | 2004-08-06 | 2006-02-16 | Janssen Pharmaceutica, N.V. | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
US8426429B2 (en) | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US8383637B2 (en) | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
ATE482936T1 (de) | 2004-08-06 | 2010-10-15 | Janssen Pharmaceutica Nv | Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate |
US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
US20060074105A1 (en) | 2004-09-20 | 2006-04-06 | Serenex, Inc. | Substituted quinoline and quinazoline inhibitors of quinone reductase 2 |
JP2008526999A (ja) | 2005-01-19 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病治療用ベータ−セクレターゼインヒビターとして活性な置換へテロ環含有三級カルビナミン |
JP5058991B2 (ja) | 2005-06-29 | 2012-10-24 | コンプメディクス リミテッド | 導電ブリッジを備えるセンサ・アセンブリ |
EP1966198B1 (en) | 2005-10-25 | 2011-03-16 | Janssen Pharmaceutica NV | 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace) |
US7868022B2 (en) | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
US7776882B2 (en) | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
WO2007092839A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | Macrocycle derivatives useful as inhibitors of beta-secretase (bace) |
CN101925578B (zh) | 2008-01-28 | 2012-11-28 | 詹森药业有限公司 | 可用作β-分泌酶(BACE)抑制剂的6-取代-硫代-2-氨基-喹啉衍生物 |
JP2011510993A (ja) | 2008-01-29 | 2011-04-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | β−セクレターゼ(BACE)阻害剤として有用な2−アミノ−キノリン誘導体 |
-
2005
- 2005-08-04 US US11/197,615 patent/US8436006B2/en active Active
- 2005-08-08 WO PCT/US2005/028191 patent/WO2006017836A2/en active Application Filing
- 2005-08-08 PL PL05785256T patent/PL1776349T3/pl unknown
- 2005-08-08 DE DE602005024004T patent/DE602005024004D1/de active Active
- 2005-08-08 PT PT05785256T patent/PT1776349E/pt unknown
- 2005-08-08 JP JP2007525074A patent/JP4884387B2/ja not_active Expired - Fee Related
- 2005-08-08 EP EP05785256A patent/EP1776349B1/en active Active
- 2005-08-08 DK DK05785256.8T patent/DK1776349T3/da active
- 2005-08-08 RS RS20100564A patent/RS51630B/en unknown
- 2005-08-08 CN CNA2005800341221A patent/CN101035771A/zh active Pending
- 2005-08-08 ES ES05785256T patent/ES2351667T3/es active Active
- 2005-08-08 AT AT05785256T patent/ATE483692T1/de active
- 2005-08-08 SI SI200531177T patent/SI1776349T1/sl unknown
-
2010
- 2010-11-05 HR HR20100595T patent/HRP20100595T1/hr unknown
-
2011
- 2011-01-04 CY CY20111100022T patent/CY1111086T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1776349T1 (sl) | 2011-01-31 |
ES2351667T3 (es) | 2011-02-09 |
WO2006017836A3 (en) | 2006-06-29 |
WO2006017836A2 (en) | 2006-02-16 |
PL1776349T3 (pl) | 2011-04-29 |
EP1776349A2 (en) | 2007-04-25 |
US8436006B2 (en) | 2013-05-07 |
US20060178383A1 (en) | 2006-08-10 |
PT1776349E (pt) | 2010-12-06 |
ATE483692T1 (de) | 2010-10-15 |
DE602005024004D1 (de) | 2010-11-18 |
DK1776349T3 (da) | 2011-01-24 |
JP2008509165A (ja) | 2008-03-27 |
JP4884387B2 (ja) | 2012-02-29 |
CN101035771A (zh) | 2007-09-12 |
RS51630B (en) | 2011-08-31 |
CY1111086T1 (el) | 2015-06-11 |
EP1776349B1 (en) | 2010-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100595T1 (hr) | Derivati 2-amino-kinazolina koji se koriste kao inhibitori beta-sekretaze (bace) | |
HRP20100594T1 (hr) | Derivati 2-amino-kinazolina koji se koriste kao inhibitori b-sekretaze (bace) | |
AU2016203192B2 (en) | Bicyclo[3.2.1]octyl amide derivatives and uses of same | |
TW200740806A (en) | Bridged N-cyclic sulfonamido inhibitors of gamma secretase | |
ES2403185T3 (es) | Nuevos derivados de 2-amino-quinazolina útiles como inhibidores de ss-secretasa (BACE) | |
RU2006146632A (ru) | Производные хиназолинона, полезные в качестве ванилоидных антагонистов | |
HRP20050708A2 (en) | Piperidine-benzenesulfonamide derivatives | |
HRP20110958T1 (hr) | 4-fenilaminokinazolin-6-ilamidi | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
RS53061B (en) | INHIBITORI PROTEIN KINAZE | |
HRP20100153T1 (hr) | Antagonisti kemokin receptora | |
CA2732806A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
CA2565599A1 (en) | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors | |
PE20060488A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasa | |
BR9205752A (pt) | Novos compostos herbicidamente, acaricidamente e inseticidamente ativos | |
AR081374A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
AR074231A1 (es) | Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos. | |
AR032475A1 (es) | Un compuesto derivado de quinazolina, su uso, procedimiento para prepararlo, y una composicion farmaceutica que lo comprende | |
NO20084517L (no) | Substituerte bifenylkarboksylsyrer og derivater derav | |
HRP20110938T1 (hr) | Spojevi koji sadrže gvanidin i koji se koriste kao agonisti muskarinskih receptora | |
PE20220934A1 (es) | Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3) | |
EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
EA202092052A1 (ru) | Производные 2,4-диаминохиназолина и варианты их применения в медицине | |
HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora |